DiagnoCure Q4 Revenues Slide 59 Percent, Terminates Deal with Signal Genetics | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer diagnostic development firm DiagnoCure said after the close of the market on Friday that its fiscal fourth-quarter revenues fell 59 percent year over year.

For the three months ended Oct. 31, the Quebec City, Quebec-based firm posted C$142,995 (US$145,306) in revenues, down from C$345,923 in Q4 2011. All revenues resulted from licensing agreements in the recently completed quarter, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.